Expression of Ki-67 Protein in Adenocarcinoma ofEsophagogastric Junction and its Correlation withClinicopathological Features and Prognosis

In order to analyze the expression of nuclear-associated antigen Ki-67 protein in adenocarcinoma of esophagogastric junction and its correlation with clinicopathological features and prognosis, immunohistochemistry was used to detect the expression of nuclear-associated antigen Ki-67 protein in 165 tissues of adenocarcinoma of esophagogastric junction. The clinical data such as age, gender, tumor size, differentiation degree, pathological stage, TNM stage, lymphatic metastasis, surgical approaches and overall survival(OS) of 165 cases of adenocarcinoma of esophagogastric junction patients admitted to the First Affiliated Hospital of Guangdong Pharmaceutical University from January 2007 to June 2015 were analysed, retrospectively. Kaplan-Meier was used for univariate survival analysis and Cox regression was used for multivariate survival analysis to explore the independent risk factors for the prognosis of adenocarcinoma of esophagogastric junction. The value of p<0.05 was considered to be statistically significant. Over-expression of nuclear-associated antigen Ki-67 protein was found in 54.5 % of primary adenocarcinoma of esophagogastric junction, which was related to the tumor size, lymphatic metastasis and recurrence and metastasis. The OS of the high expression group was lower than that of the low expression group. From the multivariate logistic regression analysis, the tumor differentiation (B: 0.912, OR: 0.402, OR 95 % CI 0.199-0.810, P=0.011) and nuclear-associated antigen Ki-67 expression (B: 0.860, OR: 2.364, OR 95 % CI 1.145-4.881, P= 0.020) were independent risk factors influencing the prognosis of adenocarcinoma of esophagogastric junction (p<0.05). The over-expression of nuclear-associated antigen Ki-67 plays a key role in the occurrence and development of adenocarcinoma of esophagogastric junction. It is an independent factor affecting the prognosis of adenocarcinoma of esophagogastric junction and provides theoretical support for the targeted treatment of adenocarcinoma of esophagogastric junction.